![]() |
||||
|
Emergent Technologies has acquired extensive experience and expertise in the evolving carbohydrate research development field over the past 5 years. Emergent Technologies currently manages and directs a unique group of glycosaminoglycan portfolio companies. Collectively Emergent Technologies and its portfolio companies have patents covering unique synthesis techniques for carbohydrate compounds such as heparin, chondroitin, hyaluronic acid and associated chimeric derivatives. Emergent Technologies leverages this expertise across multiple industrial and general consumer application arenas and is positioned to serve as an international carbohydrate innovation clearinghouse. Dr. Paul L. DeAngelis serves as the Chief Scientist of Heparinex. Dr. DeAngelis is a recognized leader in the glycobiology field and has been directly involved in commercializing technologies associated with heparin, chondroitin, and hyaluronic acid developed in his laboratories.
For more information visit the following link: http://w3.ouhsc.edu/biochem/DeAngelis.htm Visit related companies
Emergent
Technologies, Inc., Hyalose
L.L.C. and |
Copyright ©2009 Heparinex, L.L.C.. All rights reserved. Please read our Privacy Policy. Contact Us.